Sanofi announced on February 17, 2026, that it has filed its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).
The company stated that these documents are available on its website at https://www.sanofi.com/en/investors/reports-and-publications/financial-reports-and-regulated-information. Additionally, the Form 20-F can be accessed on the SEC’s website and the “Document d’Enregistrement Universel” is available on the AMF’s website. Sanofi also noted that hard copies of these documents, which include complete audited financial statements, can be obtained free of charge upon request.
Sanofi described itself as an R&D driven, AI-powered biopharma company focused on improving lives and generating growth. According to Sanofi: “We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.”
Sanofi shares are listed on EURONEXT under SAN and NASDAQ under SNY.
Media inquiries can be directed to Sandrine Guendoul or Léo Le Bourhis at Sanofi. Investor relations contacts include Thomas Kudsk Larsen, Alizé Kaisserian, Keita Browne, Nathalie Pham, Nina Goworek, Thibaud Châtelet, and Yun Li.
